文献速递血栓与止血贫血与红细胞疾病白血病

E2112:内分泌治疗联合恩替诺特或安慰剂治疗激素受体阳性晚期乳腺癌的随机III期试验

E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group.
PubMed 文献 · J Clin Oncol · 2021-08-06

PURPOSE: Endocrine therapy resistance in advanced breast cancer remains a significant clinical problem that may be overcome with the use of histone deacetylase inhibitors such as entinostat.…

要点

  • 在AI耐药晚期HR阳性/HER2阴性乳腺癌中,依西美坦联合恩替诺特未改善PFS或OS。
  • 恩替诺特组常见3/4级不良事件包括中性粒细胞减少(20%)和低磷血症(14%)。
  • 药效学分析证实恩替诺特在治疗患者中实现了靶点抑制。

核心结论

  • 依西美坦联合恩替诺特未改善AI耐药晚期HR阳性/HER2阴性乳腺癌患者的生存。

研究设计与样本

  • 患者随机接受依西美坦25 mg每日口服联合恩替诺特5 mg每周口服(EE组)或安慰剂(EP组)。
  • 主要终点为中央评估的无进展生存(PFS)和总生存(OS)。

主要发现

  • 客观缓解率为5.8%(EE组)和5.6%(EP组)。
  • EE组最常见3/4级不良事件包括中性粒细胞减少(20%)、低磷血症(14%)、贫血(8%)、白细胞减少(6%)、疲乏(4%)、腹泻(4%)和血小板减少(3%)。
  • 药效学分析证实恩替诺特治疗患者中靶点抑制。

临床怎么用

  • 对于非甾体类AI治疗后进展的HR阳性/HER2阴性晚期乳腺癌,不推荐依西美坦联合恩替诺特。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Endocrine therapy resistance in advanced breast cancer remains a significant clinical problem that may be overcome with the use of histone deacetylase inhibitors such as entinostat. The ENCORE301 phase II study reported improvement in progression-free survival (PFS) and overall survival (OS) with the addition of entinostat to the steroidal aromatase inhibitor (AI) exemestane in advanced hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. PATIENTS AND METHODS: E2112 is a multicenter, randomized, double-blind, placebo-controlled phase III study that enrolled men or women with advanced HR-positive, HER2-negative breast cancer whose disease progressed after nonsteroidal AI. Participants were randomly assigned to exemestane 25 mg by mouth once daily and entinostat (EE) or placebo (EP) 5 mg by mouth once weekly. Primary end points were PFS by central review and OS. Secondary end points included safety, objective response rate, and lysine acetylation change in peripheral blood mononuclear cells between baseline and cycle 1 day 15. RESULTS: Six hundred eight patients were randomly assigned during March 2014-October 2018. Median age was 63 years (range 29-91), 60% had visceral disease, and 84% had progressed after nonsteroidal AI in metastatic setting. Previous treatments included chemotherapy (60%), fulvestrant (30%), and cyclin-dependent kinase inhibitor (35%). Most common grade 3 and 4 adverse events in the EE arm included neutropenia (20%), hypophosphatemia (14%), anemia (8%), leukopenia (6%), fatigue (4%), diarrhea (4%), and thrombocytopenia (3%). Median PFS was 3.3 months (EE) versus 3.1 months (EP; hazard ratio = 0.87; 95% CI, 0.67 to 1.13; P = .30). Median OS was 23.4 months (EE) versus 21.7 months (EP; hazard ratio = 0.99; 95% CI, 0.82 to 1.21; P = .94). Objective response rate was 5.8% (EE) and 5.6% (EP). Pharmacodynamic analysis confirmed target inhibition in entinostat-treated patients. CONCLUSION: The combination of exemestane and entinostat did not improve survival in AI-resistant advanced HR-positive, HER2-negative breast cancer.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Connolly RM, Zhao F, Miller KD, et al. E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group. J Clin Oncol. 2021. PMID: 34357781. doi:10.1200/JCO.21.00944

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。